Biovail to Host Conference Call to Discuss Significant Product Line Acquisition; Call To Be Held Tuesday, January 2, 2001 at 8:15 a.m.Business Editors & Health/Medical Writers TORONTO--(BW HealthWire)--Dec. 29, 2000 Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency ) (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BVF) today announced that Eugene Melnyk, Chairman of the Board, Bob Podruzny, President and Chief Operating Office, Brian Crombie, Senior Vice President and Chief Financial Officer and Ken Howling, Vice President of Finance will be hosting a conference call Tuesday, January 2, 2001 at 8:15 a.m. to discuss the acquisition of a significant North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. product line. Biovail invites interested stakeholders to participate in the call as follows: -- Please call 1-800-851-6286. Canadian and International callers please dial 303-267-1000 prior to 8:15 a.m. (Eastern Standard Time). Please provide the teleconferencing Operator with the Passcode, which is "BVF". -- If you are unable to participate in the call, you will be able to listen to a replay until 7:00 p.m. (Eastern Standard Time) on Thursday, January 4th, 2001 by calling 1-800-625-5288 (303-804-1855 for International and Canadian callers) and using the identification code No. 896823 or through our website at www.biovail.com. Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of drug products utilizing advanced drug delivery technologies. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion